{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:20:57Z","timestamp":1772756457783,"version":"3.50.1"},"reference-count":42,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2006,6,9]],"date-time":"2006-06-09T00:00:00Z","timestamp":1149811200000},"content-version":"vor","delay-in-days":830,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Addiction Biology"],"published-print":{"date-parts":[[2004,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Many clinicians appear to be concerned about the potential hepatotoxicity of the opiate antagonist naltrexone (NTX) and this may be one reason why it is not used more widely in treating both heroin and alcohol abusers. Some much\u2010quoted early studies noted abnormalities in liver function tests (LFTs) in very obese patients taking high doses, although there was no evidence of clinically significant liver dysfunction. These concerns may be reinforced by advice in the UK product information sheet to perform LFTs before and during treatment, by high infection rates with hepatitis C virus (HCV) among injecting heroin addicts and by the frequency of abnormal LFTs in alcohol abusers. We describe a heroin abuser in whom clinical and laboratory manifestations of acute hepatitis B and C appeared a few days after the insertion of a subcutaneous naltrexone implant. A decision was made not to remove the implant but the hepatitis resolved completely and uneventfully well within the normal time\u2010scale. A review of the literature indicates that even when given at much higher doses than are needed for treating heroin or alcohol abusers, there is no evidence that NTX causes clinically significant liver disease or exacerbates, even at high doses, serious pre\u2010existing liver disease. During the past decade, NTX has been shown to be safe and effective in the treatment of pruritus associated with severe jaundice caused by severe and sometimes life\u2010threatening cirrhosis and other liver diseases. Its safety, even in these extreme conditions, is particularly reassuring. We suggest that it may be more appropriate and economical to advise patients to report promptly any suspected side effects than to perform regular LFTs, which may be misleading.<\/jats:p>","DOI":"10.1080\/13556210410001674130","type":"journal-article","created":{"date-parts":[[2004,4,21]],"date-time":"2004-04-21T14:29:37Z","timestamp":1082557777000},"page":"81-87","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Naltrexone: report of lack of hepatotoxicity in acute viral hepatitis, with a review of the literature"],"prefix":"10.1111","volume":"9","author":[{"given":"Colin","family":"Brewer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Voi Shim","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,6,9]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0740-5472(94)00077-8"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1353-1131(96)90012-7"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0740-5472(97)00020-2"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1080\/09595230096138"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1992.tb03316.x"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200014050-00001"},{"key":"e_1_2_1_8_2","first-page":"19","article-title":"Effects of long term therapy with naltrexone on body weight in obesity","volume":"384","author":"Atkinson RL","year":"1985","journal-title":"Clin Pharm Ther"},{"key":"e_1_2_1_9_2","first-page":"66","article-title":"Naltrexone hydrochloride (Trexan): a review of serum transaminase elevations at high dosage NIDA","volume":"67","author":"Pfohl DN","year":"1986","journal-title":"Res Monogr"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-3223(87)90127-2"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0740-5472(85)90036-4"},{"key":"e_1_2_1_12_2","first-page":"73","article-title":"Trexan): a review of hepatotoxicity issues NIDA Res Monogr Monogr","volume":"67","author":"Verebey KG","year":"1986","journal-title":"Res Monogr"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1521-0391.1997.tb00388.x"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1988.tb03102.x"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1515\/DMDI.1991.9.2.161"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1994.tb04002.x"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.1994.tb00102.x"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1992.01820110040006"},{"key":"e_1_2_1_19_2","first-page":"1123","article-title":"study): a pilot feasibility study","volume":"27","author":"COMBINE research group Testing combined pharmacotherapies and behavioral interventions for alcohol dependence (the COMBINE study): a pilot feasibility study Alcohol Clin Exp Res Res","year":"2003","journal-title":"Alcohol Clin Exp Res"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ALC.0000075548.83053.A9"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1997.01830240090013"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200212000-00009"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200207000-00008"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200109000-00006"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v63n0413"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1352\/0895-8017(2000)105<0103:LEONOS>2.0.CO;2"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199610000-00008"},{"key":"e_1_2_1_28_2","first-page":"453","article-title":"Naltrexone has no hepatotoxic effects in a self\u2010injurious patient with chronic hepatitis","volume":"13","author":"Hetrick W","year":"1993","journal-title":"J Clin Psychopharmaco"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.1998.tb03703.x"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002130100909"},{"key":"e_1_2_1_31_2","first-page":"1660","article-title":"Implantasjon av naltrexonkapsler [Implantation with naltrexone pellets]","volume":"123","author":"Waal H","year":"2003","journal-title":"Tidsskr Nor Laegefore"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1997.v113.pm9322521"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(99)70117-9"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-200111000-00022"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-200103000-00011"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(02)00318-5"},{"key":"e_1_2_1_37_2","first-page":"479","article-title":"Effect of methadone or naltrexone on the course of transaminases in parenteral drug users with hepatitis C virus infection","volume":"197","author":"Lozano Polo JL","year":"1997","journal-title":"Rev Clin Esp"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1080\/13556210220139541"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2000-10423"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840220312"},{"key":"e_1_2_1_41_2","first-page":"446","article-title":"Hepatite fulminante au paracetamol a dose therapeutique favorisee par la prise d'inducteurs enzymatiques chez une malade atteinte de cirrhose [Fulminant hepatitis following therapeutic doses of paracetamol facilitated by enzyme induction in a cirrhotic patient]","volume":"19","author":"Hastier P","year":"1995","journal-title":"Gastroent Clin Bio"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-104-6-826"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1080\/13556219971506"}],"container-title":["Addiction Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1080%2F13556210410001674130","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1080\/13556210410001674130","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T21:54:44Z","timestamp":1700171684000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1080\/13556210410001674130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,3]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,3]]}},"alternative-id":["10.1080\/13556210410001674130"],"URL":"https:\/\/doi.org\/10.1080\/13556210410001674130","archive":["Portico"],"relation":{},"ISSN":["1355-6215","1369-1600"],"issn-type":[{"value":"1355-6215","type":"print"},{"value":"1369-1600","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,3]]},"assertion":[{"value":"2006-06-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}